HCV Drug Update: Daklinza Gets Europe Approval
Bristol-Myers Hepatitis C Treatment Gets Europe Approval
Daklinza Drug Combination Has Shown Strong Cure Rates, Company Says
By Michael Calia
August 27, 2014
European regulators have approved a Bristol-Myers Squibb Inc. BMY +0.22% drug for use in hepatitis C combination treatments, the company said Wednesday.
The ruling by the European Commission allows for the drug, Daklinza, to be marketed in all of the European Union’s member states, Bristol said.
Continue reading this entire article: